You are here

Low-cost production of rApoA-IM for the treatment of cardiovascular disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL120349-01A1
Agency Tracking Number: R43HL120349
Amount: $260,890.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
320 East Vine Drive
FORT COLLINS, CO 80524-2311
United States
DUNS: 932816929
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (916) 838-3467
Business Contact
Phone: (970) 818-7010
Research Institution

DESCRIPTION (provided by applicant): Vascular diseases such as athersclerosis are the major causes of morbidity and mortality worldwide. The high density lipoprotein (HDL) particle is thought to protect the arteries from atherosclerosis by removing excesscholesterol and other lipids from the vessel wall and delivering them to the liver for elimination. The key protein component of HDL is apolipoprotein A-I (ApoA-I). A naturally occurring genetic variant, named ApoA-I Milano (ApoA-IM) is highly potent in reducing atherosclerotic vascular disease. This specific function of ApoA-IM and the HDL particle has become an important therapeutic focus in the HDL-based therapies. However, production of ApoA-IM is extremely difficult and costly thus limiting its therapeutic potential. Ventria Bioscience has developed a plant-based protein expression system in rice grain that produces recombinant protein generally 25 to 1000 fold higher than other plant-based protein expression systems. We hypothesize that we can use

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government